In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...

Getting ready for a HackerEarth assessment can feel a bit daunting, right? You want to show what you know, but the format and the pressure can be a lot. This guide is here to break down how to ...

Andrew Joseph covers health, medicine, and the biopharma industry in Europe. You can reach Andrew on Signal at drewqjoseph.45. LONDON — In the year-plus since Najat Khan joined the AI-focused drug ...

After a challenging 12 years trying to use AI to create new medicines, cofounder Chris Gibson stepped down as CEO last week. Can R&D chief and new CEO Najat Khan turn it around? In 2014, Recursion ...

Recursion Pharmaceuticals remains a high-cash-burn, premium-valued biotech with unproven clinical success despite a recent 47% rally. RXRX's next 18 months are catalyst-rich, but key pipeline assets ...

In an era dominated by social media, misinformation has become an all too familiar foe, infiltrating our feeds and sowing seeds of doubt and confusion. With more than half of social media users across ...

Getting started with LeetCode can feel like a lot, especially if you’re just beginning your coding journey. So many problems, so many concepts – it’s easy to get lost. But don’t sweat it. This guide ...

Every time a new slang word gets coined on the Internet, linguist Adam Aleksic is thrilled. “It’s definitely good for me in that I stay in business,” says Aleksic, who studies the origins of words and ...

During the last three months, 4 analysts shared their evaluations of Recursion Pharmaceuticals (NASDAQ:RXRX), revealing diverse outlooks from bullish to bearish. The table below provides a snapshot of ...

Recursion Pharmaceuticals is laying off a fifth of its workforce in connection with a previously announced streamlining of the AI biotech’s pipeline. Shrinking the Salt Lake City-based company’s ...

As of March 31, Recursion Pharmaceuticals had a cash position of $509 million. Following Tuesday’s layoffs, the biotech expects its runway to last into the fourth quarter of 2027. Recursion ...